iSpecimen Inc. (ISPC)
| Market Cap | 3.81M -38.5% |
| Revenue (ttm) | 466,302 -92.1% |
| Net Income | -11.42M |
| EPS | -21.95 |
| Shares Out | 5.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 114,985 |
| Open | 0.6900 |
| Previous Close | 0.6965 |
| Day's Range | 0.6300 - 0.6900 |
| 52-Week Range | 0.6300 - 27.4440 |
| Beta | 1.78 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 27, 2026 |
About ISPC
iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. The company’s marketplace offers human biospecimens, including biofluids, such as whole blood, plasma, serum, urine, saliva, sputum, naso... [Read more]
Financial Performance
In 2025, iSpecimen's revenue was $1.93 million, a decrease of -79.24% compared to the previous year's $9.29 million. Losses were -$10.49 million, -16.09% less than in 2024.
Financial StatementsNews
iSpecimen Expands Into AI-Powered Drug Discovery and Disease Trend Monitoring With Acquisition of Foldlab AI Products
New Agentic AI tools for protein discovery and disease trend prediction take iSpecimen beyond its biospecimen marketplace Woburn, Massachusetts--(Newsfile Corp. - November 5, 2026) - iSpecimen Inc. (...
iSpecimen Transcript: EGM 2026
Stockholders approved a proposal authorizing a 1-for-10 to 1-for-100 reverse split, with the board to set the exact ratio. Final certified voting results were slated for disclosure in a Form 8-K within four business days.
iSpecimen Proxy statement: Proxy filing
iSpecimen filed a proxy statement on October 30, 2026, providing details for shareholder voting and corporate governance matters.
iSpecimen Offers Next-Day Healthy Donor Blood and Launches Development of AI Agent
Woburn, Massachusetts--(Newsfile Corp. - October 29, 2026) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), a provider of human biospecimens, today announced expanded access to fully co...
iSpecimen Proxy statement: Proxy filing
iSpecimen filed a proxy statement on October 19, 2026, providing details for shareholder voting and corporate governance matters.
iSpecimen Transcript: AGM 2026
Stockholders preliminarily approved the securities issuance, future-financing, asset-acquisition and adjournment proposals. The reverse-split vote remained open until Oct. 30, 2026, with the meeting adjourned only on that item.
iSpecimen Proxy statement: Proxy filing
iSpecimen filed a proxy statement on October 9, 2026, providing details for shareholder voting and corporate governance matters.
iSpecimen Supports Hospital Validation of New Chemistry Analyzer
Company coordinates collection of more than 1,700 human specimens to support new laboratory testing capabilities Woburn, Massachusetts--(Newsfile Corp. - September 29, 2026) - iSpecimen, a provider of...
iSpecimen Proxy statement: Proxy filing
iSpecimen filed a proxy statement on September 14, 2026, providing details for shareholder voting and corporate governance matters.
iSpecimen Proxy statement: Proxy filing
iSpecimen filed a proxy statement on September 4, 2026, providing details for shareholder voting and corporate governance matters.
iSpecimen completes international cancer research project
iSpecimen (ISPC) recently completed an international cancer research project involving hundreds of cancer blood specimens, with the samples shipped within three weeks of receiving the purchase order. ...
iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks
Woburn, MA, Aug. 20, 2026 (GLOBE NEWSWIRE) -- iSpecimen, a provider of human biospecimens, recently completed an international cancer research project involving hundreds of cancer blood specimens, wit...
iSpecimen Quarterly report: Q2 2026
iSpecimen has published its Q2 2026 quarterly earnings report on August 14, 2026.
iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants
WOBURN, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical ...
E.F. Hutton & Co. Acts as Exclusive Placement Agent for $5.0 Million Public Offering for iSpecimen
NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F.
E.F. Hutton & Co. Acts as Acts as Exclusive Placement Agent for $5.0 Million Public Offering for iSpecimen
Transaction Marks E.F. Hutton's Third Capital Markets Engagement with iSpecimen Since December 2025 Transaction Marks E.F. Hutton's Third Capital Markets Engagement with iSpecimen Since December 2025
iSpecimen prices $5M offering of common stock, warrants
iSpecimen (ISPC) announced the pricing of its public offering of approximately $5M of the company’s common stock, and/or pre-funded warrants to purchase shares of common stock at a public offering…
iSpecimen Registration statement: Registration filing
iSpecimen filed a registration statement on July 17, 2026, providing details about a securities offering with the SEC.
iSpecimen Registration statement: Registration filing
iSpecimen filed a registration statement on July 6, 2026, providing details about a securities offering with the SEC.
iSpecimen files to sell 1.54M shares of common stock
E.F. Hutton is exclusive placement agent in connection with the offering.
iSpecimen Registration statement: Registration filing
iSpecimen filed a registration statement on June 24, 2026, providing details about a securities offering with the SEC.
iSpecimen files to sell 488,290 shares of common stock for holders
17:27 EDT iSpecimen (ISPC) files to sell 488,290 shares of common stock for holders
iSpecimen Registration statement: Registration filing
iSpecimen filed a registration statement on June 4, 2026, providing details about a securities offering with the SEC.
iSpecimen Proxy statement: Proxy filing
iSpecimen filed a proxy statement on May 18, 2026, providing details for shareholder voting and corporate governance matters.
iSpecimen Quarterly report: Q1 2026
iSpecimen has published its Q1 2026 quarterly earnings report on May 18, 2026.